Self-administered Biologicals

Chart_Collage_160   Published March 2016  •  Catalog no. SAB474K •  Price US $3,850

The growth of biological drug products is having a significant effect on the way drugs and devices are developed and commercialized. The clinical application of these drugs is often limited by a lack of desirable attributes for adequate absorption or distribution. Cooperation between device designers and drug developers is occurring much earlier in the drug development cycle, allowing device designs in many cases to be tailored to the bioavailability targets and pharmacokinetic profiles of specific drug therapies. The powerful physiological effects of antibodies, hormones and other biological drugs also increase the need for safety and adherence, escalating the importance of downstream product decisions.

Bar_Graph  Self-administered Biologicals Report Prospectus (Download PDF)

Blue document  Self-administered Biologicals Report Order Form (Download PDF)

What You Will Learn

• What biological drugs are currently marketed for self-administration, how are they positioned in the market, who markets them and what are the product specifics?
• Who are the important biological drug suppliers, their collaborations and their capabilities?
• What are the major factors driving biological drug demand?
• How important are drug developer-ecosystem partner relationships and what are the key alliances in the industry?
• What are the essential design factors, material selection issues, technologies and market development issues for biological drug products?
• How are biological drugs aligned with various drug classes and therapeutic markets?
• What are the significant economic, technology, and regulatory factors affecting biological drugs?

Summary of Contents

Executive Summary

Biological Drug Market Dynamics

Evolution in Drug Demand
The Growth of Self Administration
Market Drivers
Competitive Landscape

Self-administered Biologicals – Product Factors

Stability/Shelf Life
Packaging Strategies
Device Selection
Specific Patient Populations

Self Administered Biologicals – Delivery Strategies
Prefilled Syringes
Cartridge-based Injectors
Product-specific Devices

SA Biologicals – Product & Strategy Assessments

IgG1 mAbs
IgG2 mAbs
GLP-1 Receptor Agonists
Fusion Proteins
TNF Inhibitors

A Look Ahead – Development-stage SA Biologicals

Therapeutic Sector Analysis & Forecasts

Autoimmune Diseases
Hormone Therapy
Infectious Diseases
Metabolic Conditions

Market Factors

Regulatory Issues
Device Branding & DTC Marketing
Patient Compliance and Ease of Use
Healthcare Economics

Company Profiles